SuperworthInMed Pharmaceuticals INM
- Market cap
- $7.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
InMed Pharmaceuticals' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $901.9K+181% | $1.2M+164% | $1.2M+13% | $1.3M−45% | $1.3M+40% | $1.1M−10% | $1.3M+8% | $1.3M+2% | $1.1M−11% | $820.2K−26% | n/a | n/a | |
| Cost of revenue | $880.6K+9% | $916.1K+171% | $883.1K+5% | $817K+10% | $771.2K−12% | $650.8K−29% | $1.1M+23% | $728.1K−11% | $717K−7% | $636K−2% | n/a | n/a |
| Gross profit | $21.2K | $324.1K+147% | $289.5K+50% | $466.1K−70% | $493.4K+2223% | $460.9K+42% | $175.6K−39% | $576.7K+24% | $403.2K−18% | $184.2K−60% | n/a | n/a |
| R&D | $1.3M−6% | $609.8K−28% | $656.8K−25% | $1.2M+93% | $700.1K−46% | $895.2K+47% | $425.4K−35% | $577.3K−52% | $581.6K−17% | $630.6K−30% | $1M+140% | $805.7K+40% |
| SG&A | $1.3M−17% | $1.4M−7% | $1.4M−3% | $1.2M−14% | $1.5M+15% | $1.7M+26% | $1.6M+15% | $1.3M+4% | $1.5M+3% | $1.6M−6% | $1.7M+10% | $2.4M+87% |
| −$2.6M−25% | −$1.7M−24% | −$1.8M−16% | −$2M+289% | −$1.8M−33% | −$2.2M+29% | −$2.1M+18% | −$1.8M−8% | −$1.8M+1% | −$2.1M−4% | n/a | n/a | |
| Pre-tax income | −$2.5M−28% | −$1.5M−30% | −$1.7M−14% | −$1.9M+474% | −$1.7M−34% | −$2.6M+74% | −$2.1M+20% | −$1.8M−5% | −$1.7M+3% | −$2M−21% | −$2.8M+35% | −$4.8M+164% |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$2.5M−28% | −$1.5M−30% | −$1.7M−14% | −$1.9M+473% | −$1.7M−34% | −$2.6M+74% | −$2.1M+23% | −$1.8M−8% | −$1.7M+3% | −$2M−21% | −$3M+40% | −$5.8M+227% |
| −$15.24−81% | −$3.71−80% | −$3.58−70% | −$4.03+102% | −$2.71−82% | −$3.64−2% | −$1.94−46% | −$1.20−70% | −$0.44−84% | −$0.51−86% | −$0.73−62% | −$1.33+11% | |
| 166.4K+285% | 398.7K+247% | 480.6K+189% | 480.6K+189% | 620.1K+273% | 706.5K+77% | 1.1M+128% | 1.5M+211% | 4M+538% | 4M+460% | 4M+269% | 4.7M+215% |
Operating income: 18 periods, Q1 FY22 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 11 periods, Q4 FY20 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY20 to Q4 FY26: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: share-days: the 12-month average over 365 days less the 9-month over 274, the two on one basis (x25). Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest InMed Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| INMInMed Pharmaceuticals | $7.9M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on InMed Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .